Company / Operating Cash Flow
Syndax Pharmaceuticals Inc Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$323.0M
FY2025
5-year range
-$323.0M / -$50.6M
FY2021-FY2025
Trend
-17.5%
vs FY2024
Sector context
#196 of 216
Health Care
What the data says
Among 216 Health Care companies, Syndax Pharmaceuticals Inc is in the bottom 9% for operating cash flow. Operating Cash Flow has declined for 4 consecutive years, from -$51M in FY2021 to -$323M in FY2025.
Based on SEC 10-K filings.
-$323M in FY2025.
Declined from -$161M to -$323M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 216This company -$323.0M Sector average $658.7M
▼
-149.0% below sector average
Key checks
Key Insights
- Syndax Pharmaceuticals Inc's operating cash flow has declined for 4 consecutive years.
- In FY2025, operating cash flow decreased 17.5% year-over-year.
- Ranks #196 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$323.0M | -17.5% |
| FY2024 | -$274.9M | -71.2% |
| FY2023 | -$160.6M | -20.1% |
| FY2022 | -$133.7M | -164.1% |
| FY2021 | -$50.6M | +26.1% |
| FY2020 | -$68.5M | -44.7% |
| FY2019 | -$47.4M | -34.7% |
| FY2018 | -$35.2M | -1348.0% |
| FY2017 | -$2.4M | +83.1% |
| FY2016 | -$14.4M | -492.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026